JP2005534344A5 - - Google Patents

Download PDF

Info

Publication number
JP2005534344A5
JP2005534344A5 JP2004548269A JP2004548269A JP2005534344A5 JP 2005534344 A5 JP2005534344 A5 JP 2005534344A5 JP 2004548269 A JP2004548269 A JP 2004548269A JP 2004548269 A JP2004548269 A JP 2004548269A JP 2005534344 A5 JP2005534344 A5 JP 2005534344A5
Authority
JP
Japan
Prior art keywords
trpm4b
monovalent cation
protein
trpm4b channel
modulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004548269A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005534344A (ja
JP4540481B2 (ja
Filing date
Publication date
Priority claimed from US10/142,649 external-priority patent/US7452675B2/en
Application filed filed Critical
Publication of JP2005534344A publication Critical patent/JP2005534344A/ja
Publication of JP2005534344A5 publication Critical patent/JP2005534344A5/ja
Application granted granted Critical
Publication of JP4540481B2 publication Critical patent/JP4540481B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004548269A 2002-05-02 2003-05-02 TRPM4bモジュレータをスクリーニングする方法 Expired - Fee Related JP4540481B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37793702P 2002-05-02 2002-05-02
US10/142,649 US7452675B2 (en) 2002-01-25 2002-05-08 Methods of screening for TRPM4b modulators
PCT/US2003/015321 WO2004039941A2 (en) 2002-05-02 2003-05-02 METHODS OF SCREENING FOR TRPM4b MODULATORS

Publications (3)

Publication Number Publication Date
JP2005534344A JP2005534344A (ja) 2005-11-17
JP2005534344A5 true JP2005534344A5 (enExample) 2006-06-22
JP4540481B2 JP4540481B2 (ja) 2010-09-08

Family

ID=32232958

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004548269A Expired - Fee Related JP4540481B2 (ja) 2002-05-02 2003-05-02 TRPM4bモジュレータをスクリーニングする方法

Country Status (6)

Country Link
US (2) US7452675B2 (enExample)
EP (1) EP1573322B1 (enExample)
JP (1) JP4540481B2 (enExample)
AU (1) AU2003301688B2 (enExample)
CA (1) CA2483961C (enExample)
WO (1) WO2004039941A2 (enExample)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050048615A (ko) * 2002-08-19 2005-05-24 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
AU2007267546B2 (en) * 2006-05-25 2013-05-16 The Queen's Medical Center Methods of screening for TRPM4 modulators of insulin secretion
CA2766409C (en) 2009-07-03 2023-04-25 Avipep Pty Ltd Immuno-conjugates and methods for producing them
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
CA2784610C (en) 2009-12-23 2020-07-14 Avipep Pty Ltd Immuno-conjugates and methods for producing them
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP2640727B1 (en) 2010-11-17 2015-05-13 Genentech, Inc. Alaninyl maytansinol antibody conjugates
CA2833404A1 (en) 2011-04-21 2012-10-26 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using them b
EP2707723B1 (en) 2011-05-12 2016-02-10 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
JP6104257B2 (ja) 2011-10-14 2017-03-29 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピンおよびそのコンジュゲート
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
DK2906298T3 (en) 2012-10-12 2018-12-17 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
PT2906253T (pt) 2012-10-12 2018-11-05 Medimmune Ltd Conjugados de anticorpo anti-psma de pirrolobenzodiazepina
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
KR101995620B1 (ko) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
AU2013366493B2 (en) 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
KR102066318B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
MX363787B (es) 2013-03-13 2019-04-03 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de los mismos.
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
BR112016012410A2 (pt) 2013-12-16 2017-09-26 Genentech Inc conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック, インコーポレイテッド 1−(クロロメチル)−2,3−ジヒドロ−1h−ベンゾ[e]インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
UA118113C2 (uk) 2013-12-16 2018-11-26 Дженентек, Інк. Пептидоміметичні сполуки та їх кон'югати антитіла з лікарським засобом
ES2796090T3 (es) 2014-02-10 2020-11-25 Inst Curie Uso de moduladores MCOLN-1 para regular la migración celular
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP2017531620A (ja) 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド システイン操作抗体及びコンジュゲート
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
JP2017533887A (ja) 2014-09-17 2017-11-16 ジェネンテック, インコーポレイテッド ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
CA2969689A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
CR20180243A (es) 2015-10-02 2018-07-31 Genentech Inc Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
JP6852065B2 (ja) 2015-10-20 2021-03-31 ジェネンテック, インコーポレイテッド カリケアマイシン−抗体−薬物コンジュゲート及び使用方法
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108700598A (zh) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
JP7043425B2 (ja) 2016-06-06 2022-03-29 ジェネンテック, インコーポレイテッド シルベストロール抗体-薬物コンジュゲート及び使用方法
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
SMT202200490T1 (it) 2017-04-18 2023-01-13 Medimmune Ltd Coniugati di pirrolobenzodiazepina
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
KR102442736B1 (ko) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제
SI3668874T1 (sl) 2017-08-18 2022-04-29 Medimmune Limited Pirolobenzodiazepinski konjugati
ES3075078T3 (es) 2017-09-20 2026-07-27 Ph Pharma Co Ltd Análogos de tailanstatina
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP2022508468A (ja) 2018-09-14 2022-01-19 ルヒゼン ファーマスティカルズ アクツィエンゲゼルシャフト Crac阻害剤およびコルチコステロイドを含む組成物ならびにそれらの使用方法
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
JP7232925B2 (ja) 2019-02-15 2023-03-03 ウーシー バイオロジクス アイルランド リミテッド 改善された均一性を有する抗体薬物コンジュゲートの調製するプロセス
CN113631560B (zh) 2019-03-15 2025-02-18 麦迪穆有限责任公司 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2022148781A1 (en) 2021-01-05 2022-07-14 Institut Curie Combination of mcoln activators and immune checkpoint inhibitors
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
CN120417934A (zh) 2022-12-23 2025-08-01 基因泰克公司 Cereblon降解剂缀合物及其用途
KR20260012304A (ko) 2023-04-17 2026-01-26 피크 바이오, 인크. 항체 및 항체-약물 접합체 및 사용 방법 및 합성 공정 및 중간체
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof
TW202617186A (zh) 2024-06-28 2026-05-01 美商飛爾富來生物公司 Bcl-xl降解劑抗體結合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
AU1741392A (en) 1991-05-07 1992-12-21 Hans H. Haraldsted Method and apparatus for reading of especially a finger print
WO1998008979A1 (en) * 1996-08-30 1998-03-05 The Regents Of The University Of California Method and compounds for controlling capacitative calcium ion entry into mammalian cells
CA2360396A1 (en) 1998-12-30 2000-07-13 Andrew M. Scharenberg Characterization of a calcium channel family
AU2001238596A1 (en) * 2000-02-22 2001-09-03 Millennium Pharmaceuticals, Inc. 18607, a novel human calcium channel

Similar Documents

Publication Publication Date Title
Mislow et al. Nesprin‐1α self‐associates and binds directly to emerin and lamin A in vitro
Chacko et al. The L3 loop and C-terminal phosphorylation jointly define Smad protein trimerization
CA2483961A1 (en) Methods of screening for trpm4b modulators
Ying et al. A stimuli-responsive nanopore based on a photoresponsive host-guest system
JP2010511382A5 (enExample)
BRPI0509193B8 (pt) método para diagnosticar doença cervical de alto grau em um paciente, e kit
ATE378420T1 (de) Mediator-stabilisierende verbindung und methoden zur verwendung zur detektion elektrochemischer analyte
JP7068829B2 (ja) 生物サンプルの生理的性質を測定するための方法および装置
KR101332847B1 (ko) 압타머를 이용한 타겟물질의 검출방법
Chai et al. CD44 expression is predictive of poor prognosis in pharyngolaryngeal cancer: systematic review and meta-analysis
CN101126758A (zh) 流式细胞术同步检测肿瘤中多种细胞蛋白表达的方法
Tanaka et al. Electrochemical detection of HbA1c, a maker for diabetes, using a flow immunoassay system
Yamaguchi et al. Pulse-chase experiment for the analysis of protein stability in cultured mammalian cells by covalent fluorescent labeling of fusion proteins
JP2021521412A5 (enExample)
Diez et al. 2-D fluorescence difference gel electrophoresis (DIGE) in neuroproteomics
ATE548457T1 (de) Peptid-basierte methode für die überwachung von genexpression in einem host
EP1715347A4 (en) PROTEIN MEASURING METHOD
WO2006022882A3 (en) Canine pancreatic lipse
Jiang et al. Arginase-flotillin interaction brings arginase to red blood cell membrane
JP2007523640A5 (enExample)
ATE535546T1 (de) Humane monoklonale antikörper, die spezifisch an ifg-ii binden
Si et al. Protein Deceleration and Sequencing Using Si3N4‐CNT Hybrid Nanopores
PT1047777E (pt) Novas moleculas de acidos nucleicos correlacionadas com o fenotipo rhesus d fraco
WO2023244680A3 (en) Reagents and methods for cell identification and characterization
JP2005508169A5 (enExample)